Patent US4271189A successfully refreshed from Google Patents.
US4271189A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lithium derivatives of taurine having reinforced neuro-muscular activity
Assignee: LES LABORATOIRES MERAM
•
Filing: 1979-12-14
•
Granted: 1981-06-02
•
Expires: 1999-12-14
Abstract
Abstract The present invention relates to derivatives of taurine represented by the general formula: (CH.sub.3 --CO--NH--CH.sub.2 --CH.sub.2 --SO.sub.3)-Li+ to the process for preparation thereof from taurine and to application thereof as drugs having a reinforced neuro-muscular activity.
Inventors
- 👤 Jean P. Durlach
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 08:20
CPC Classifications
C; C07; C07C; C07C303/00; C07C303/02; C07C303/22; A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; C07C309/00; C07C309/01; C07C309/02; C07C309/03; C07C309/13; C07C309/14; C07C309/15
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
13 words
A derivative of taurine represented by the formula: (CH.sub.3 --CO--NH--CH.sub.2 --CH.sub.2 --SO.sub.3).sup.- Li.sup.+.
Claim 2
Dependent Claim
13 words
A derivative of taurine represented by the formula: (CH.sub.3 --CO--NH--CH.sub.2 --CH.sub.2 --SO.sub.3).sup.- Li.sup.+.
Claim 3
Dependent Claim
18 words
A compound according to claim 1 used as drugs, in particular as agents having a reinforced neuromuscular activity.
Claim 4
Dependent Claim
26 words
Pharmaceutical compositions containing as active ingredient a compound according to claim 1 associated with a suitable excipient for administration by the oral, parenteral or local route.
Claim 5
Dependent Claim
41 words
Orally administered forms of the compositions according to claim 3, containing the active ingredient at the unitary dose of 0.30 g to 1 g for capsules, sugar-coated pills, tablets, gelatin-coated capsules, and from 3 to 5 g/10 ml for the solutions.
Claim 6
Dependent Claim
25 words
Parenterally administered forms of the compositions according to claim 4, containing the active ingredient at a dose of 0.5 to 2 g per injectable ampoule.
Claim 7
Dependent Claim
19 words
A method of treating manic-depressive psychosis by administering an effective amount of a compound as recited in claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-06-01 | 1984-12-01 | 1985-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-06-01 | 1988-12-01 | 1989-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-06-01 | 1992-12-01 | 1993-06-02 | $7700.00 | Window Closed / Lapsed |